JournalProtocolsCJC 1295 and Ipamorelin: The Gold Standard GH Research Protocol
Protocols

CJC 1295 and Ipamorelin: The Gold Standard GH Research Protocol

The combination of CJC 1295 and Ipamorelin is considered the gold standard for growth hormone research. This article explains why these two peptides work so well together.

Dr. James Chen

Senior Research Scientist

20 March 2026
8 min read

Why Combine GHRH and Ghrelin Mimetics?

Growth hormone release from the pituitary is regulated by two complementary pathways: the GHRH pathway (stimulatory) and the ghrelin/GHS pathway (also stimulatory, but through a different mechanism). Research has demonstrated that activating both pathways simultaneously produces a synergistic effect, with GH release significantly greater than the sum of either pathway activated alone.

CJC 1295 (Modified GRF 1 29)

CJC 1295 without DAC (also known as Modified GRF 1 29 or Mod GRF) is a synthetic analogue of GHRH. It has been modified at four positions to resist enzymatic degradation, extending its half life from minutes to approximately 30 minutes. This allows it to produce a meaningful GH pulse while still maintaining a relatively natural pulsatile release pattern.

Ipamorelin

Ipamorelin is the most selective ghrelin mimetic available. Unlike GHRP 6 or GHRP 2, Ipamorelin stimulates GH release with minimal effects on cortisol, prolactin, or appetite. This selectivity makes it ideal for research where GH specific effects need to be isolated from confounding hormonal changes.

The Synergistic Effect

When CJC 1295 and Ipamorelin are administered together, the resulting GH pulse is significantly larger than either compound alone. This synergy occurs because:

  • 1CJC 1295 primes the pituitary somatotroph cells via the GHRH receptor
  • 2Ipamorelin simultaneously activates the ghrelin receptor on the same cells
  • 3The dual activation produces amplified intracellular signalling
  • 4The result is a robust, natural pattern GH pulse
  • Research Protocol Considerations

    ParameterTypical Research Reference
    CJC 1295 dose100 to 200 mcg
    Ipamorelin dose100 to 300 mcg
    Timing2 to 3 times daily
    Optimal timingMorning, post exercise, before sleep
    Cycle duration8 to 12 weeks in research

    Pre Blended Convenience

    The CJC 1295 and Ipamorelin blend offers the convenience of a single vial with both compounds at optimised ratios. This eliminates the need for separate reconstitution, reduces preparation time, and ensures consistent dosing ratios.

    Conclusion

    The CJC 1295 and Ipamorelin combination remains the gold standard for growth hormone research due to its synergistic mechanism, high selectivity, and natural pulsatile release pattern. For researchers studying the GH/IGF 1 axis, this combination provides a powerful and well characterised tool.

    All products are for research purposes only. Not for human consumption.

    Ready to Start Your Research?

    Browse our complete range of research-grade peptides with 99%+ purity and third-party testing.